Adult Dosing

Acute otitis externa

• 4 drops in infected ear(s) bid x 7 days
• Otowick users: 8 drops in infected ear(s) bid x 7 days followed by 4 drops bid x 7 days

Pediatric Dosing

Acute otitis externa (child 1 year)

• 4 drops in infected ear(s) bid x 7 days
• Otowick users: 8 drops in infected ear(s) bid x 7 days followed by 4 drops bid x 7 days

Note:

• The safety and efficacy have not been established in infants < 1 year old

• Acute otitis externa (AOE) caused by <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i>

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to quinolones

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustment not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustment not defined

• Long term use may result in overgrowth of nonsusceptible organisms, including yeast and fungi. Suspend therapy if this happens and institute alternative therapy
• Suspend therapy if any signs of hypersensitivity are noticed and institute alternative therapy

Pregnancy Category:C

Breastfeeding: Safety Unknown; Should be used cautiously during lactation

• EENT: Ear pruritus
• GI: Nausea

• Fluoroquinolone antibiotic; inhibits bacterial type II topoisomerase enzymes (DNA gyrase and topoisomerase IV) involved in bacterial DNA replication, transcription, repair, and recombination
• Excretion: Unknown
• Metabolism: Unknown; CYP450: Unknown
• Half life: Unknown

US Trade Name(s)

• Xtoro

US Availability

Xtoro

• SUSP: 0.3 %

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Otic Anti-infectives

Infectious Disease

Otic Anti-infectives

ENT

Otic Anti-infectives